Tamibarotene clinical trials
Also written Am80 and SY-1425.
How each study uses tamibarotene is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the tamibarotene studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
16 studies that test it; most in 2021 (3)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 2 |
| 2011 | 2 |
| 2016 | 1 |
| 2021 | 3 |
| 2023 | 2 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 8
Nagoya University (3) · Syros Pharmaceuticals (3) · CytRx (2) · Rege Nephro Co., Ltd. (1) · Zeria Pharmaceutical (1) · R&R Inc. (1) · St. Marianna University School of Medicine (1) · Northwestern University (1)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test tamibarotene.
- Mar 2027Clinical Trial of AM80 in Combination With Gemcitabine, Cisplatin, and Nivolumab in Patients With Urothelial CarcinomaPhase 2 · Nagoya University
Studies
Open first, then newest update. How each study uses tamibarotene is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 16
- The Clinical Trial of Tamibarotene for Patients With HFpEF (RELIEF Trial)RecruitingPhase 2Nagoya UniversityNCT07855692Written as TamibaroteneHow we know
- Clinical Trial of AM80 in Combination With Gemcitabine, Cisplatin, and Nivolumab in Patients With Urothelial CarcinomaRecruitingPhase 2Nagoya UniversityNCT06983210Written as Add-on effect of adding tamivarotene (AM80) to gemcitabine, cisplatin, and nivolumab combination therapyHow we know
- Investigator-initiated Clinical Trial of MIKE-1CompletedPhase 1/2Nagoya UniversityNCT05064618Written as Am80How we know
- Efficacy and Safety of Tamibarotene(AM80H) for HTLV-1 Associated Myelopathy/ Tropical Spastic Paraparesis (HAM/TSP)TerminatedPhase 2/3St. Marianna University School of MedicineNCT01343355Written as TamibaroteneHow we know
- Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic SyndromeTerminatedPhase 3Syros PharmaceuticalsNCT04797780Written as TamibaroteneHow we know
- Study of Tamibarotene in Patients With ADPKDActive, not recruitingPhase 2Rege Nephro Co., Ltd.NCT06289998Written as TamibaroteneHow we know
- Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)TerminatedPhase 2Syros PharmaceuticalsNCT04905407Written as TamibaroteneHow we know
- A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic SyndromeCompletedPhase 2Syros PharmaceuticalsNCT02807558Written as TamibaroteneHow we know
- Phase I/II Study of SY-1425 (Tamibarotene) in Combination With Azacitidine and Venetoclax for Patients With Chronic Myelomonocytic LeukemiaWithdrawnPhase 1/2M.D. Anderson Cancer CenterNCT06085638Written as TamibaroteneHow we know
- Tamibarotene and Arsenic Trioxide for Relapsed Acute Promyelocytic LeukemiaTerminatedPhase 1Northwestern UniversityNCT00985530Written as TamibaroteneHow we know
- First Line Study of Tamibarotene in Combination for Advanced Non-Small Cell Lung CancerTerminatedPhase 2CytRxNCT01337154Written as TamibaroteneHow we know
- Safety, Efficacy, & Pharmacokinetic Study of Tamibarotene to Treat Patients With Relapsed or Refractory APLCompletedPhase 2CytRxNCT00520208Written as TamibaroteneHow we know
- Phase I/II Study of Z-208 in Advanced Hepatocellular Carcinoma (HCC)CompletedPhase 1/2Zeria PharmaceuticalNCT00731445Written as Z-208How we know
- Efficacy and Safety of Tamibarotene (OAM80) for Alzheimer's DiseaseStatus unknownPhase 2Osaka City UniversityNCT01120002Written as TamibaroteneHow we know
- Efficacy and Safety of Tamibarotene(AM80) for Lupus NephritisStatus unknownPhase 2Kinki UniversityNCT01226147Written as TamibaroteneHow we know
- Phase II Study of RR110 in Patients With Active Crohn's DiseaseCompletedPhase 2R&R Inc.NCT00417391Written as RR110 (Tamibarotene)How we know
What changed recently
From the registry's own updates since Oct 20, 2026.
Started recruiting1
- The Clinical Trial of Tamibarotene for Patients With HFpEF (RELIEF Trial)Oct 30, 2026NCT07855692
Codes
What other systems call tamibarotene · ClinicalTrials.gg INT003463
- MeSH (NLM) C061133tamibaroteneOne source NLM
- UNII (FDA) 08V52GZ3H9TAMIBAROTENEConfirmed FDA, NLM, Wikidata
- Wikidata Q7681221tamibaroteneConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C71025TamibaroteneOne source FDA
- DrugBank DB04942One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C061133 | tamibarotene | One source NLM |
| UNII (FDA) | 08V52GZ3H9 | TAMIBAROTENE | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q7681221 | tamibarotene | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C71025 | Tamibarotene | One source FDA |
| DrugBank | DB04942 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.